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Faster-cycling PCR formulations, protocols, and instruments have been developed to
address the need for increased throughput and shorter turn-around times for PCR-based
assays. Although run times can be cut by up to 50%, shorter cycle times have been
correlated with lower detection sensitivity and increased variability. To address these
concerns, we applied Compartmentalized Self Replication (CSR) to evolve faster-cycling
mutants of Taq DNA polymerase. After five rounds of selection using progressively shorter
PCR extension times, individual mutations identified in the fastest-cycling clones were
randomly combined using ligation-based multi-site mutagenesis. The best-performing
combinatorial mutants exhibit 35- to 90-fold higher affinity (lower Kd ) for primed template
and a moderate (2-fold) increase in extension rate compared to wild-type Taq. Further
characterization revealed that CSR-selected mutations provide increased resistance to
inhibitors, and most notably, enable direct amplification from up to 65% whole blood.
We discuss the contribution of individual mutations to fast-cycling and blood-resistant
phenotypes.
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INTRODUCTION
Taq DNA polymerase is still considered the workhorse of PCR,
providing great economy and reliability in routine amplification
of genomic targets up to 2 kb. Moreover, PCR detection in real-
time relies on Taq’s intrinsic 5′-flap endonuclease activity for
TaqMan probe hydrolysis and lack of proofreading activity to
minimize primer/probe degradation (Holland et al., 1991). With
an extension rate of 60 nt/s, wild-type Taq produces high ampli-
con yields after 30–40 cycles using 1min anneal-extension times.
Run times are 1.5–2 h on conventional Peltier-based PCR instru-
ments and approximately 1 h using advanced qPCR instrumen-
tation with improved thermal ramp rates (2.2–3◦C/s). Demand
for higher throughput and shorter turn-around-time continues to
fuel interest in developing faster PCR instrumentation, along with
polymerases with improved kinetic properties. In the near future,
microchip-based technologies are expected to provide drastically
reduced run times (<3–5min), limited only by the kinetics of
nucleotide incorporation (Hashimoto et al., 2004).
Currently, shorter qPCR run times are achieved by reduc-
ing hold times for denaturation, annealing and extension steps,
and/or by using a 2-step cycling regimen with combined anneal-
ing and extension steps (at 60◦C). Although run times can be
cut by up to 50%, shorter cycle times with Taq have been cor-
related with lower detection sensitivity and higher failure rates
when applied across a range of primer-template combinations
(Hilscher et al., 2005). Results can be further improved by increas-
ing the amount of Taq or other reagents, or by reducing reaction
volume and using thin-walled PCR tubes to further improve heat
transfer. Ultimately, however, PCR run times are limited by the
kinetic properties of the PCR enzyme. In the most telling exam-
ple, the processivity of a proofreading Family B DNA polymerase
was directly correlated to PCR cycle times. When the processiv-
ity of Pfu DNA polymerase was increased by 9-fold by fusion to a
small basic double-stranded DNA-binding protein (Sso7d), PCR
annealing/extension times could be reduced from 2min to 30 s
for a 5 kb λ target (Wang et al., 2004). Unfortunately, this strategy
could not be employed to accelerate TaqMan assays, as Pfu lacks
5′ endonuclease activity and Sso7d fusions to full-length Taq are
unstable (data not shown).
To accelerate qPCR run times, we applied the Compar-
tmentalized Self Replication (CSR) technique (Ghadessy et al.,
2001) to evolve faster-cycling Taq mutants. CSR employs emul-
sion PCR to trap individual E. coli cells harboring mutant poly-
merase genes in microscopic aqueous compartments along with
nucleotides and pol gene-specific primers. When the emulsion
is cycled under selective conditions, active mutant polymerases
self-replicate and are enriched, while those with insufficient activ-
ity fail to replicate and are lost from the gene pool. CSR has
been used to successfully evolve Taq mutants with increased
thermostability or heparin resistance (Ghadessy et al., 2001),
and chimeric polymerases that are broadly resistant to complex
environmental inhibitors or can process non-canonical primer-
template duplexes and bypass lesions found in ancient DNA such
as abasic sites (d’Abbadie et al., 2007). In this study, we used CSR
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to evolve Taq mutants that can self-replicate under progressively
shorter extension times. As we will show, CSR selection netted Taq
variants with a broad range of beneficial attributes, in addition to
increased polymerization rate.
MATERIALS AND METHODS
All molecular biology reagents were from Agilent Technologies
unless otherwise noted. Oligonucleotides were purchased
from Integrated DNA Technologies. Radioactive nucleotides
[γ33P] ATP-3000 Ci/mmol-1 mCi (NEG302H001MC) and
deoxythymidine-5′-triphosphate [Methyl-3H] tetrasodium salt-1
mCi (NET221A001MC) were purchased from Perkin Elmer.
RANDOM AND SITE-DIRECTED MUTAGENESIS
Taq mutants were generated by random mutagenesis of
the Thermus aquaticus pol I gene using the GeneMorph
II random mutagenesis kit and PCR primers that intro-
duce XbaI and SalI sites and an N-terminal His6 tag
(F: GGCGGCTCTAGATAACGAGGGCAAAAAATGCATCATCA
TCACCATCAC, R: GCGGTGCGGAGTCGACTTACTCCTTGGC
GGAGAGCCAGTC). PCRs also included 5%DSMO and increas-
ing amounts of plasmid template (10 ng, 1 ng, 0.1 ng) to generate
libraries with varying mutation rates of 4.7–6.2 per kb. After
DpnI treatment, PCR products were gel purified and digested
with XbaI and SalI (NEB). Purified fragments were cloned into
the pASK-IBA5C expression vector (IBA) and transformed into
XL10-Gold Kan cells. Site-directed mutagenesis was performed
using the QuikChange Lightning or QuikChange LightningMulti
Site-Directed Mutagenesis kit.
CSR SELECTION
Approximately 250,000 independent clones were scraped from
plates, re-suspended, and stored as glycerol stocks. LB/CAM cul-
tures (40ml) were freshly inoculated, grown at 30◦C to OD600 of
0.6, and induced with 200 ng/ml anhydrotetracycline. After 3 h of
growth, cells were harvested and washed in 1× Taq buffer. CSR
was carried out essentially as described by Ghadessy et al. (2001).
To select for faster-cycling mutants, extension times were succes-
sively reduced over five rounds of CSR from 2.5min (round 1) to
15 s (round 5). PCR selection was performed on a Robocycler 96
using 2.5min at 94◦C followed by 30 cycles of 45 s at 94◦C, 30 s at
60◦C, and 0.25–2.5min at 72◦C.
PROTEIN EXPRESSION
Colonies expressing mutant Taq polymerases were randomly
picked, replicated, and then grown overnight at 30◦C in 96-
deep well plates (VWR) containing 750μl LB/CAM. Overnight
cultures (30μl) were inoculated into fresh media, induced with
anhydrotetracycline at OD600nm of 0.3–0.5, and grown overnight
with shaking at 30◦C. Cells were collected and used to prepare
lysates for direct PCR screening or for affinity protein purifica-
tion (see below). Cell pellets were re-suspended in 50μl Tris pH 8
containing 4mg/ml lysozyme, and incubated at 37◦C for 10min
to disrupt cell walls and at 75◦C for 15min to inactivate E. coli
protein. Lysates were clarified by centrifugation for 15–30min at
4000 RPM through a 96-well filter plate (Millipore, Multiscreen
HTS, HV).
PURIFICATION OF HIS-TAGGED Taq MUTANTS
Cell pellets were re-suspended in 90μl of buffer prepared
by adding one cOmplete EDTA-free Protease Inhibitor tablet
(Roche) to 50ml of 50mM Tris pH 8, 0.5M NaCl, 5mM imi-
dazole. An aliquot (60μl) of 1× FastBreak Cell Lysis Reagent
(Promega) was added and the lysate was incubated at 37◦C for
15min and at 70◦C for 15min, before centrifugation through
a Millipore 96-well filter plate. Clarified lysates were combined
with 60μl Ni-NTA agarose (Qiagen) and incubated with shaking
at room temperature for 2 h. After collecting the agarose resins
using a fresh filter plate, resins were washed two times with 200μl
wash buffer (50mM Tris pH8, 0.5M NaCl, 20mM imidazole)
and eluted with 80μl of 50mM Tris pH8, 0.5M NaCl, 200mM
imidazole.
FAST PCR SCREENING
Taq mutants were screened by amplifying a 549 bp GAPDH tar-
get on the Mx3005 qPCR system using fast-cycling conditions
consisting of 1min at 95◦C followed by 50 cycles of 2 s at 99◦C,
7 s at 59◦C. PCRs (25μl) contained 1× Taq buffer (15mM Tris
pH 8.0, 50mM KCl, 2.5mM MgCl2, 0.01% Tween-20), 0.8mM
dNTPs, GAPDH primers (5′-ATCTTGAGGCTGTTGTCATAC;
5′-CAGGAAACAGCTATGACCATG), 105 copies plasmid DNA,
0.8× Eva Green, and either 2μl clarified lysate (neat or diluted
1:5) or 10–50 ng of purified His-tagged Taq. Primary hits dis-
played earlier Cqs compared to wild-type Taq controls processed
in the same way on the same plates.
COLUMN PURIFICATION OF NON-TAGGED Taq MUTANTS
Mutant pol genes were subcloned into pET11 (with no His tag)
and expressed in E. coli strain BL21-DE3-RIPL. One liter cultures
were grown at 30◦C in LB medium with 125μg/ml ampicillin
and 30μg/ml chloramphenicol, and induced at OD600nm of 0.6
with 1mM IPTG for 4–5 h. Cell pellets were recovered by cen-
trifugation and stored at −20◦C. For purification, pellets were
suspended in Buffer A (50mM Tris-Cl pH 8.2, 1mM EDTA,
10mM 2-mercaptoethanol) plus cOmplete Protease Inhibitor
(Roche). Cell suspensions were disrupted by sonication, brought
to 0.2M with solid (NH4)2SO4, heated in a water bath at 80◦C
for 15min, and then cooled on ice. Polyethyleneimine was added
to 0.2% (w/v), and after mixing thoroughly, insoluble mate-
rial was removed by centrifugation. The supernatant was loaded
on an SP Sepharose FastFlow (GE Healthcare) column equi-
librated and run with Buffer B (50mM Tris-Cl pH8, 1mM
EDTA, 0.2M (NH4)2SO4, 10mM 2-mercaptoethanol, 5% glyc-
erol). Flow-through fractions were pooled and dialyzed against 15
volumes (with two changes) of Buffer C (50mM Tris-Cl pH8.3,
1mM EDTA, 10mM 2-mercaptoethanol, 5% glycerol), and then
loaded on Q Sepharose HP (GE Healthcare) equilibrated with
Buffer C. The column was eluted with a 12.5 column-volume
gradient to Buffer C containing 400mM KCl. Taq-containing
fractions (as judged by SDS-PAGE) were pooled, diluted with
2.5 volumes of Buffer D (50mM Tris-Cl pH 7.5, 1mM EDTA,
10mM 2-mercaptoethanol, 5% glycerol, 125mM KCl) and then
loaded on Heparin Sepharose HP (GE Healthcare). The col-
umn was eluted with a 25 column-volume gradient to Buffer D
with 650mM KCl. Substantially-pure Taq-containing fractions
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were pooled, dialyzed into storage buffer (20mM Tris-Cl pH
8, 0.1mM EDTA, 1mM DTT, 100mM KCl, 50% glycerol), and
stored at−20◦C. Protein was quantified using the Coomassie Plus
protein assay (Thermo Fisher Scientific).
REAL-TIME PCR ASSAYS
SYBR Green qPCR reactions (20μl) consisted of 10–20 ng wild-
type or mutant Taq, 0.5–50 ng human genomic DNA, 200μM
each dNTP, 600 nM total primers, 1× Taq buffer (adjusted to
95mM KCl for all PCRs and biochemical assays employing
Taq mutants), and 0.24× SYBR Green. Primer sequences were
as follows: ABC (F: 5′-CCAAACCCTGGATCACGTGTT-3′;




(F: 5′-AGCCTAGCTCCAGTGCTTCTAGTA-3′; R: 5′-CTTTGG
ATGAGGAGCCGATATTG-3′), Numb (F: 5′-GAGGTTCCTA
CAGGCACCTGCCCAG-3′; R: 5′-CAAAATCACCCCTCACAG
TACTCTG-3′). TaqMan qPCR reactions consisted of 10 ng
wild-type or mutant Taq, human genomic DNA, 0.8mM dNTPs,
1× Taq buffer (adjusted to 95mM KCl for Taq mutants), and 1×
β-actin primer/probe (171 bp) from Life Technologies’ Assays-
On-Demand. qPCR reactions were run on the StepOnePlus
(Life Technologies) or CFX96 (BioRad) instrument using cycling
parameters indicated in the Figure legends.
PRIMER EXTENSION ASSAYS
Extension rate and processivity were measured at 70◦C using
M13mp18 template DNA (NEB), pre-annealed at a 1.3–1.5:1
molar ratio to a 5′ 33P-labeled primer with the sequence 5′-
GGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGC-
3′. Extension reactions (80μl) consisting of 1.75 pmol primed
M13, 200μM each dNTP, and 1× Taq buffer were brought to
70◦C prior to adding 0.55 pmol Taq enzyme. Aliquots (8μl)
were removed at 15, 30, 45, 60, 90, and 120 s and quenched
with 50mM EDTA. Extension products were denatured at
80◦C for 3min and analyzed on 1% alkaline-agarose gels to
determine mean fragment length. Extension rates were calculated
as number of nucleotides incorporated divided by incubation
time. Processivity assays were conducted similarly using 1.1 pmol
primed M13 and limiting amounts of Taq (template/enzyme
molar ratios of 37:1, 370:1, 3700:1). Aliquots removed at various
time points (15, 30, and 60 s) were quenched in gel loading buffer,
and analyzed on 6% TBE-Urea gels (Life Technologies). Median
processivity was determined from reactions producing the same
product length over several time points or enzyme amounts.
NUCLEOTIDE INCORPORATION ASSAYS
Polymerase cocktails (10μl) contained 200μM dATP, dGTP and
dCTP, 100μMTTP (3H-TTP), 1× Taq buffer (adjusted to 95mM
KCl for Taq mutants), and fixed or varying concentrations of
primed (non-radiolabeled) M13 DNA for half-life (T1/2) or Kcat
measurements, respectively. Steady-state kinetic parameters were
determined using 0.005 pmol Taq and 0.5–100 nM primed M13.
After 3min at 60◦C, incorporation reactions were quenched with
ice-cold 0.1M EDTA and 5μl aliquots spotted on DE-81 filters.
After washing 5 times with 2× SSC, incorporated radioactiv-
ity was measured by scintillation counting. Km and Vmax values
were determined from Lineweaver-Burk plots, and Kcat was cal-
culated as maximum number of nucleotides incorporated per
Taqmolecule per second (Vmax/[Taq]). To determine T1/2(95◦C),
Taq was pre-heated in the absence or presence of genomic
DNA before residual DNA polymerase activity was assayed as
described above. Mixtures (10μl) consisting of 0.02 pmol Taq,
1× Taq buffer, and 0 or 10 ng human genomic DNA were over-
laid with mineral oil and incubated at 95◦C for 5–180min. At
various time points, aliquots (2μl) were transferred to poly-
merase assay cocktail (10μl) containing 0.05 pmol primed M13.
Polymerase activity (CPM) was plotted against pre-incubation
time at 95◦C.
Kd ASSAY
Dissociation constant Kd (DNA) was measured using a gel
mobility-shift assay that employs a 5′ 33P-labeled hairpin
template (5′-CTCCAGACACGACGCAGTTGCCCGATGGTC
GACGTTCGCGAAAGCGAACGTCGACCATCGGGCAACT-3′)
blocked at the 3′ end with dideoxy TMP. The radiolabeled
hairpin (0.25 nM) was incubated with varying concentrations
of wild-type or mutant Taq DNA polymerases (0.5–1000 nM;
bracketing the predicted Kd) in 1× Taq buffer at 37◦C for 30min.
DNA-protein complexes were run on 10% non-denaturing TBE
gels (Life Technologies) in 0.5× TBE buffer. Gels were dried
down and exposed to film. The fraction of DNA bound was
quantified by densitometry using AlphaView SA software (Alpha
Innotech), and then plotted against enzyme concentration to
determine Kd values by interpolation.
PCR/qPCR INHIBITION ASSAYS
Xylan, humic acid, CTAB, and dextran sulfate were purchased
from Sigma. Blood was collected from healthy human volunteers
using BD Vacutainer tubes with EDTA or heparin. Inhibitor-
resistance screens (“spike-in” assays) were conducted by adding
varying concentrations of inhibitors to qPCRs (20μl) contain-
ing 20 ng wild-type or mutant Taq DNA polymerase, 200μM
each dNTP, 1× Taq buffer, 0.24× SYBR Green, 105 copies plas-
mid DNA, and 600 nM GAPDH primers (5′-ATCTTGAGGC
TGTTGTCATAC; 5′-CAGGAAACAGCTATGACCATG) designed
to amplify 549 bp GAPDH target on the Mx3005 qPCR system
using 2min initial denaturation at 95◦C followed by 40 cycles of
12 s at 95◦C and 60 s at 60◦C.
Endpoint PCRs directly from blood (endogenous targets) con-
sisted of (50μl) 50 ng DNA polymerase, 15mM Tris pH 8.8,
50mM (wild-type Taq) or 95mM (mutant Taq) KCl 2.5mM
MgCl2, 0.02% Tween-20, 200μM each dNTP, and 2% DMSO. A
322 bp IGF target was amplified directly from blood using 400 nM
each primer (IGF322-F 5′-ATGGAGGGACCAATAGTAGGGAA;
IGF322-R 5′-AGTACCACGTACAGGCTTTGCAT), and the fol-
lowing cycling parameters: 5min at 90◦C followed by 30 cycles
of 30 s at 95◦C, 30 s at 60◦C, 1min at 72◦C. Water (25μl) was
added to PCRs containing blood before centrifugation to pel-
let debris. A portion (12μl) of each sample was run on a 4%
Nusieve® (3:1) TBE agarose gel (Lonza). Comparisons employing
commercial enzymes were conducted using the 232 bp Quantos
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(see above) assay system and each manufacturer’s recommended
reaction buffer and cycling conditions.
RESULTS
Taq MUTAGENESIS AND SCREENING
We used the CSR technique to evolve mutants of Taq DNA
polymerase that self-replicate using abbreviated extension times.
Faster-replicating mutant polymerases are expected to provide
robust performance with “fast” PCR instruments and cycling
conditions. Moreover, identifying mutations that allow shorter
cycle times may provide insight on kinetic factors that limit PCR
performance of wild-type Taq.
Taq mutant libraries were subject to CSR selection using pro-
gressively shorter extension times, ranging from 1min down to 6 s
per kb of taq pol I. After rounds 2, 4, and 5, crude protein prepara-
tions were prepared and tested in amplifications employing 2-step
cycling with 2 s denaturation and 7 s annealing-extension times.
To account for differences in protein expression, lysates were pre-
pared and assayed at least 2–3 times before affinity-purifying the
top-performing Taq mutants. From a screen of several hundred
clones, we recovered 24 His-tagged Taq mutants that consistently
produce earlier Cq values compared to wild-type Taq in real-time
PCR under fast cycling conditions. DNA sequencing identified 8
mutations that appear in 2 or more independent clones, as fol-
lows (in order of frequency): E507K (11); G59W (9); L245M (5);
V155I, L375V, F749I (4); K508R, E734G (2).
To identify the most effective mutation or combination of
mutations, we performedmulti-sitemutagenesis with an equimo-
lar mixture of 8 mutant primers to create all possible (single, dou-
ble, triple, etc.) combinations of G59W, V155I, L245M, L375V,
E507K, K508R, E734G, and F749I mutations. The combinato-
rial library was enriched by 1 round of CSR selection using 15 s
(6 s per kb) extension times, and random clones were screened
as described above with a modified Taq PCR reaction buffer.
We increased KCl concentration from 50 to 95mM to eliminate
non-specific amplification products that were generated by the
majority of fast-cycling mutants (<30% of total amplified prod-
uct as judged by agarose gels or qPCR melt curves; data not
shown). Higher KCl concentrations (>50mM) inhibit wild-type
Taq DNA polymerase to the extent where no PCR products are
generated at 95mMKCl. The most active Taqmutants (1C2, 2C2,
3B, 42; see Table 1) were sub-cloned to remove the His-tag, puri-
fied using a standard wild-type Taq protocol, and characterized
further by PCR.
In endpoint PCRs employing longer (>1 kb) genomic tar-
gets, Taq 1C2, 2C2, 3B, and 42 efficiently amplified targets using
15–30 s/kb extension times whereas Taq required 1min/kb to
generate similar yields (data not shown). Taq 1C2, 2C2, 3B,
and 42 were also tested with shorter targets to assess the bene-
fits of fast cycling in quantitative PCR (qPCR) assays that tra-
ditionally employ targets of <300 bp (SYBR Green detection)
or<200 bp (probe detection) to achieve amplification efficiencies
as close to 100% as possible. In qPCRs employing SYBR Green,
Taq readily amplifies genomic DNA targets up to 300 bp using
standard anneal-extension times of 1min at 60◦C (Figure 1).
However, with 10 s anneal-extension times, Taq produced slightly
lower Rn values in the 109 bp COMTE assay and completely
failed to amplify a 305 bp NUMB target (Figures 2B,C). In
contrast, Taq 1C2, 2C2, 3B, and 42 amplified the entire series
(91–305 bp) of genomic DNA targets using abbreviated cycle
times (10 s, Figure 2; 1 s, Figure 1), and no significant differences
were observed among the mutants with respect to Cqs, Rn val-
ues, and amplification efficiencies. Compared to SYBR Green
assays, abbreviated cycle times appear to have less of an impact
in TaqMan assays designed according to standard primer-probe
design rules (<200 bp targets). In the example shown in Figure 3,
Taq 1C2, 2C2, 3B, and 42 produce equivalent results to wild-type
Taq using 10 s anneal-extension times, thereby confirming that
probe-hydrolysis (5′-structure-specific endonuclease) activity is
not affected by the fast-cycling mutations.
MUTATIONS CONFERRING THE FAST-CYCLING PHENOTYPE
DNA sequencing revealed that 3 of the original 8 mutations-
L245M, E507K, and F749I- are absolutely conserved in Taq 1C2,
2C2, 3B, and 42, indicating that one or more are essential for
fast-cycling under CSR selection conditions (Table 1). While not
critical, other mutations emerging from CSR selection may fur-
ther enhance overall fitness of the Taq 245M/507K/749I mutants.
For example, G59W (missing in Taq 3B) and/or V155I (missing in
Taq 42) appear inmajority (3 out of 4) of the top-performers, sug-
gesting a role for these N-terminal domain mutations in enhanc-
ing robustness. The L375V, K508R, and E734G mutations appear
less frequently, and may be of limited importance to survival dur-
ing CSR selection. Figure 4A shows the location of G59W, V155I,
and L245M in the N-terminal 5′–3′ endonuclease domain, and
the close proximity of E507K and F749I in the thumb and fingers
domains, respectively.
To further elucidate the contribution of individual mutations
to the fast-cycling phenotype, we constructed and purified indi-
vidual mutants TaqG59W, Taq V155I, Taq E507K, and Taq F749I.
When equivalent amounts of enzyme were compared in qPCRs,
only Taq E507K amplified 286 and 232 bp genomic DNA targets
with short (1 s) anneal-extension times (Figure 1 and data not
shown). Moreover, Taq E507K produced equivalent Cq values to
Table 1 | Taq mutations.
Enzyme G59W V155I L245M L375V E507K K508R E734G F749I
Taq (wt) − − − − − − − −
Taq 42 + − + + + + + +
Taq 3B − + + − + − − +
Taq 2C2 + + + + + − + +
Taq 1C2 + + + − + − − +
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FIGURE 1 | Fast cycling conferred by E507K mutation. Genomic
DNA targets were amplified as described in Methods using 10 ng
human gDNA and 20 ng of purified wild-type or mutant Taq DNA
polymerase. Reactions were cycled on the CFX96 instrument (BioRad)
using cycling conditions consisting of 3min at 95◦C followed by 40
cycles of (left panels) 10 s at 95◦C, 1 s at 60◦C; or (right panels)
10 s at 95◦C, 60 s at 60◦C. Genomic DNA targets are as follows:
(A) 286 bp Aldolase; and (B) 232 bp Quantos.
Taq 42, 2C2, and 3B, indicating that the E507K mutation is solely
responsible for the fast-cycling phenotype. With standard cycle
times (60 s anneal-extension), amplification profiles are compa-
rable across all Taq enzymes, confirming that single-site mutants
Taq G59W, Taq V155I, and Taq F749I retain wild-type levels of
polymerase activity.
KINETIC PARAMETERS OF Taq MUTANTS
Kinetic parameters were investigated at each enzyme’s KCl opti-
mum (50 or 95mM for Taq or Taq mutants, respectively) to
determine how E507K confers the fast-cycling phenotype. In
radio-labeled primer extension assays, Taq E507K and Taq 42
exhibit somewhat higher (1.7-fold) polymerization rates com-
pared to wild-type Taq (85 vs. 50 nt s−1; Table 2), but no change
in processivity (20 bases; Table 2). Measurements of steady-state
kinetic parameters also show a moderate (2.2-fold) increase in
Kcat values (2.5 ± 0.03 s−1 for Taq 42; 1.1 ± 0.04 s−1 for Taq; data
not shown). The most compelling difference between wild-type
and E507K mutants was observed in gel-based Kd assays employ-
ing a hairpin oligonucleotide template. As shown in Table 2,
dissociation constants for Taq 42, 1C2, and E507K mutants (2.75,
1.9, and 1.1 nM, respectively) were approximately 35–90-fold
lower compared to those of Taq and Taq G59W (102 and 91 nM,
respectively). Moreover, Kd measurements were comparable for
assays run in the absence or presence of dNTPs (data not shown).
In sum, these results indicate that the E507K mutation sup-
ports faster PCR cycling conditions by increasing binding affinity
of Taq for primed DNA templates irrespective of nucleotide
binding.
MUTATIONS IMPROVING POLYMERASE FITNESS
CSR has been shown to exert strong selective pressure on poly-
merase fitness, enriching for variants that self-replicate with
sufficient accuracy and efficiency to remain in the gene pool
(Ghadessy et al., 2001). In some cases, selected traits evolved in
parallel with increased inhibitor resistance, presumably because
survival requires self-replication in the presence of CSR emul-
sifiers/stabilizers and bacterial debris (Baar et al., 2011). In our
study, several mutations including G59W, V155I, L245M, and
F749I emerged during selection of the fast-cycling phenotype,
prompting speculation that one or more of these ancillary muta-
tions may enhance overall fitness of Taq DNA polymerase. To
address this possibility, we further characterized the stability and
inhibitor-resistance of a subset of Taqmulti-site mutants.
Thermostability was investigated by determining half-life
(T1/2) at 95◦C, in the absence and presence of DNA template.
Compared to wild-type, Taq 42 exhibits a slightly higher T1/2 in
the presence of DNA (71 ± 4.6 vs. 60 ± 1.7min), but no signifi-
cant difference in the absence of DNA (60.5 ± 2.3 vs. 62 ± 2min;
data not shown). These results are consistent with increased
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FIGURE 2 | Fast qPCR assays employing SYBR Green. Genomic DNA
targets were amplified as described in Methods using 0.5 ng human gDNA
and 10ng of purified wild-type or mutant Taq DNA polymerase. Reactions
were cycled on the StepOnePlus instrument (Life Technologies) using
cycling conditions consisting of 3min at 95◦C followed by 40 cycles of 3 s at
95◦C, 10 s at 60◦C. Genomic DNA targets are as follows: (A) 91 bp ABC, (B)
109 bp COMTE2, (C) 305 bp Numb. Sixty second extension time is required
for Taq wild-type to efficiently amplify the 305 bp target (data not shown).
thermal resistance conferred by tighter binding (of E507K
mutants) to DNA, but also imply that none of the other muta-
tions in Taq 42 (G59W, V155I, L245M, L375V, K508R, E734G,
F749I) enhance intrinsic thermal resistance. Next, inhibitor resis-
tance of Taq 2C2 (all mutations except K508R) was investigated
by amplifying an exogenous target in the presence of varying
amounts of known Taq inhibitors, including plant-associated
substances (xylan, dextran sulfate, CTAB), soil inhibitors (humic
acid), whole blood treated with various anti-coagulants, and
other PCR inhibitors (NaCl, SYBR Green) (Demeke and Adams,
1992; Watson and Blackwell, 2000; Kermekchiev et al., 2009).
In these studies, inhibitor resistance was determined relative to
wild-type Taq using standard PCR cycling times. Compared to
wild-type Taq, Taq 2C2 shows significantly (≥4-fold) higher tol-
erance to dextran sulfate (50-fold; data not shown), NaCl (4-fold;
Table 3), and whole blood (see below).
FIGURE 3 | Fast cycling with TaqMan detection. An Assays-on-Demand
assay (Life Technologies; 171 bp β-actin target) was performed using 50, 5,
0.5 ng human genomic DNA and 10ng of purified wild-type or mutant Taq
DNA polymerase. Reactions were cycled on the StepOnePlus instrument
using cycling conditions consisting of 2min at 95◦C followed by 40 cycles
of: (A) 10 s at 95◦C, 60 s at 60◦C; or (B) 10 s at 95◦C, 10 s at 60◦C.
Additional testing with single- andmulti-site mutants revealed
that E507K confers increased tolerance to NaCl (up to 100mM)
in addition to higher affinity for primed-template. In contrast,
mutations at other positions result in equivalent (V155I, F749)
or reduced (Taq G59W; by 2.5-fold) tolerance to NaCl compared
to wild-type Taq. Next, resistance to blood-associated inhibitors
was investigated in more depth by amplifying endogenous tar-
gets directly from blood (EDTA tubes). As shown in Figure 5,
the E507K mutation also provides increased tolerance to blood,
allowing amplification of a 322 bp IGF target from up to 45%
EDTA-blood. Resistance to blood may be partly explained by
higher salt tolerance, as the amount of NaCl introduced with
22.5μl blood is within the range (up to 100mM; Table 3) toler-
ated by Taq E507 (67.5mM NaCl final). Interestingly, individual
mutations at G59W, V155I, and F749I also confer significant
resistance to EDTA-blood, albeit less than E507K (15% compared
to 45%), perhaps reflecting intrinsic sensitivity to NaCl (toler-
ate <10–25mM, while 15% blood introduces 22.5mM NaCl). In
contrast, wild-type Taq fails to amplify the 322 bp endogenous
target from as little as 1% EDTA-blood (Table 3), consistent with
previous reports (Al-Soud and Radstrom, 1998; Kermekchiev
et al., 2009). In total, these results indicate that G59W, V155I, and
F749I mutations confer significant (>10–15-fold) resistance to
blood-associated inhibitors through a mechanism that is distinct
from E507K (unrelated to increased binding affinity and salt resis-
tance). Moreover, when the majority of CSR-selected mutations
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FIGURE 4 | Location of E507K and blood-resistant mutations in Taq
crystal structure. “Fitness mutations” G59W, V155I, L245M, and F749I
reside in the 5′–3′ exonuclease and Fingers domains, respectively, while
fast-cycling mutation E507K is in the thumb domain (A) (Kim et al., 1995).
E507 resides in close proximity to the primer portion of the primer-template
duplex (B) (Li et al., 1998).
Table 2 | Kinetic parameters of wild-type and mutant Taq
polymerases.
Enzyme Extension rate (nt/s) Processivity (nt) Kd [DNA] (nM)
Taq (wt) 50 20 102
Taq 42 85 20 2.75
Taq 1C2 ND ND 1.9
E507K 85 20 1.1
G59W ND ND 91.6
ND, Not Determined.
are added to E507K, resistance increases from 45% (Taq E507K)
to between 50% (Taq 3B; 3 additional mutations) and 60–65%
(Taq 1C2, 2C2, 42; 4–6 additional mutations).
The fast-cycling Taq mutants were found to be much less
resistant to heparinized blood. The difference was more pro-
nounced for single-site mutants (≤2% for heparinized blood
vs. 15–45% EDTA-blood) than for combinatorial mutants (10–
30% vs. 50–65% for heparin- vs. EDTA-blood, respectively).
Presumably, heparinized blood poses a greater challenge due
Table 3 | Resistance of Taq mutants to blood and NaCl*.
Enzyme EDTA blood (%) Heparinized blood (%) NaCl (mM)
Taq (wt) <1 <1 25
Taq 42 60 10 100
Taq 3B 50 10 100
Taq 2C2 65 25 100
Taq 1C2 60 30 100
E507K 45 2 100
F749I 15 2 25
V155I 15 <2 25
G59W 15 2 10
*The values represent the highest inhibitor concentration beyond which PCR
amplification is inhibited.
to the combined effects of these known inhibitors (blood and
heparin; Satsangi et al., 1994). Resistance to heparinized blood
decreases in the following order: 1C2, 2C2 (25–30%) > 42, 3B
(10%) > G59W, E507K, F794I (2%) > V155I (≥1%) > wild-
type Taq (<1%; Table 3), indicating that additional mutations
(along with E507K) are essential to overcoming the inhibitory
burden posed by heparinized blood. Taq 1C2 DNA polymerase
has been incorporated into a commercially-available master mix
(SureDirect PCR, Agilent Technologies), designed for amplifica-
tion of genomic targets including cfDNA from large volumes of
blood. When compared to other blood PCR kits, we found the
majority can amplify the 232 bp Quantos target from 2.5 and 25%
EDTA- and heparin-treated blood (Figure 6). Only the Taq 1C2-
based formulation could amplify an endogenous target from 45%
blood (heparin-treated).
DISCUSSION
In this report, we describe the properties of Taq DNA poly-
merase mutants evolved to self-replicate under abbreviated cycle
times. Mutations emerging from CSR selection (G59W, V155I,
L245M, L375V, E507K, K508R, E734G, F749I) were randomly
combined and subjected to a final round of selection employ-
ing 15 s anneal-extension times. The fastest-cycling combina-
torial mutants (Taq 42, 1C2, 2C2, and 3B) were shown to
readily amplify genomic DNA targets up to 300 bp using abbre-
viated (≤10 s hold times) two-step cycling protocols on fast-
ramping instruments (Figures 1, 2). When tested individually,
the fast-cycling phenotype could be attributed solely to the
E507K mutation (Figure 1B). Further characterization revealed
that compared to wild-type, TaqE507K exhibits a dramatic (∼90-
fold) reduction in Kd for primer-template (measured in the
absence of nucleotides), and only moderate (∼1.7-fold) or no
improvement in polymerization rate or processivity, respectively.
These findings suggest that Taq’s affinity for primed-template,
rather than catalytic rate, is a limiting factor in PCR amplification
under fast-cycling conditions.
A previous study concluded that E507 plays a role in primer-
template binding, as substitution of E for Q improves Taq’s
RNA-dependent 5′ nuclease activity without altering DNA-
dependent 5′ nuclease activity or RNA- and DNA-dependent
DNA polymerase activities (Ma et al., 2000). This result would
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FIGURE 5 | Amplification directly from blood. A 322bp IGF target was
amplified from 5 to 25μl EDTA-blood using 50 ng of each mutant Taq DNA
polymerase. Reactions were cycled on the SureCycler 8800 using the
following parameters: 5min at 90◦C, followed by 30 cycles of 30 s at 95◦C,
30 s at 60◦C, 60 s at 72◦C. Wild-type Taq can amplify the 322 bp from human
genomic DNA in the absence of blood, but not in the presence of 1% blood
(data not shown), even though the amount of EDTA introduced with 0.5μl
EDTA-blood (0.089mM EDTA) is well below inhibitory levels.
FIGURE 6 | Comparison of commercial enzymes for blood PCR. A 232bp
single-copy target was amplified (50μl) from the indicated volumes of blood
using SureDirect PCR mix (A) or another commercially-available PCR blood
kits (B–E). All reactions contained 0.4μM each Quantos primer and were
cycled on a SureCycler 8800 instrument, according to each manufacturer’s
recommendations. PCRs performed with SureDirect PCR master mix were
cycled as follows: 5min at 90◦C, followed by 30 cycles of 30 s at 94◦C, 30 s
at 60◦C, 60 s at 72◦C. The other commercial kits employ 3-step cycling and
30 cycles, with hold times ranging between 5 and 60 s (annealing) and 15–60
(extension), respectively.
be expected if the amino acid side chain at position 507 comes
in close proximity to the template strand, and substituting amine
for negatively-charged oxygen reduces discrimination against the
2′OH of the ribose sugar. The crystal structure of Taq large frag-
ment shows that E507 resides in the H1H2 loop of the thumb
domain, which interacts with the distal portion of the primer-
template duplex in both open and closed forms of binary and
ternary complexes (Li et al., 1998). In this model, the peptide
carbonyl of E507 comes in close proximity (3.8 Å) to the phos-
phate moiety between the 6th and 7th nucleotide from the 3′
end of the newly-extended primer (Figure 4B). As a whole, these
data suggest that the E507K mutation stabilizes the Taq-DNA
binary complex by forming additional contacts with the dis-
tal (away from the active site) portion of the primed-template.
Higher KCl (95mM instead of 50mM) may be required with
Taq E507K mutants to reduce binding affinity for mis-annealed
primer-template during PCR annealing steps. The importance of
E507 residue in protein/primer-template interactions has been
shown in other DNA polymerase families as well. For example,
in a study by Cozens et al. (2012), an analogs mutation to Taq
E507K was made in the thumb domain of Thermococcus gorg-
onarious (family B DNA polymerase; E664K), which transforms
Tgo into an RNA polymerase by lowering the Kd for non-cognate
RNA/DNA duplex and lowering the Km for ribonucleotide incor-
poration. This mutant was also capable of translesion synthesis
across an abasic site or thymidine dimer.
As discussed above, CSR has been shown to exert strong selec-
tive pressure on polymerase fitness, enriching for variants that
self-replicate with sufficient fidelity and catalytic efficiency to
remain in the gene pool. For example, selected traits such as
improved thermostability and increased tolerance to inhibitors
have been shown to evolve with no cost to fidelity or cat-
alytic efficiency (Kcat/Km) (Ghadessy et al., 2001; Baar et al.,
2011). CSR selection for tolerance to individual inhibitors has
also been shown to produce broad spectrum resistance, presum-
ably because survival requires self-replication in the presence
of CSR emulsifiers, stabilizers, and bacterial debris (e.g., dena-
tured protein, nucleic acid, and membrane lipid in the aqueous
PCR compartments). In a striking example, CSR selection with
bone powder produced a chimeric polymerase (2D9) with broad
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tolerance to a variety of environmental inhibitors, including
humic acid, coprolite, peat extract, clay-rich soil, cave sediment,
and tar, but surprisingly not to inhibitors in whole blood (Baar
et al., 2011). Despite 81 amino acid changes, 2D9 exhibited
comparable fidelity and processivity to wild-type Taq, consistent
with the intrinsic requirement for polymerase fitness. A broad
resistance spectrum implies a common mechanism of inhibition
(for bone and soil extracts), prompting the authors to specu-
late that non-specific binding of inhibitors to protein and/or
nucleic acidmay sequester Taq or DNA template and prevent PCR
amplification (Baar et al., 2011).
Encouraged by these reports and others, we assayed our CSR-
selected mutants for inhibitor resistance. In addition to fast-
cycling, the E507K mutation was shown to improve resistance to
NaCl (tolerates up to 100mM) and to inhibitors in whole blood
(tolerates up to 45% (v/v) EDTA-blood). Individual mutations
G59W, V155I, and F749I also confer blood resistance, but the
magnitude of improvement is less (by 3-fold) than for E507K,
and no corresponding increase in NaCl tolerance was observed
(Taq L245M not tested). Heparinized blood posed a significant
challenge due to the combined inhibitory effects of blood and
heparin, as shown by the drastic difference in blood volumes tol-
erated by Taq E507K (22.5μl EDTA-blood vs. 1μl heparin-blood
per 50μl PCR). Apparently, increased DNA-binding affinity and
NaCl-resistance conferred by the E507K substitution is insuffi-
cient to overcome the inhibitory burden, and additional muta-
tions are required for amplification from larger (>5μl) volumes
of heparinized blood. Not all mutations or mutation combina-
tions have been tested, but our results to date implicate G59W
and 1–3 additional mutations (V155I, L245M, and/or F749I)
in improving tolerance to heparinized blood. Compared to Taq
E507K, Taq 3B (E507K plus V155I, L245M, F749I) can amplify
genomic targets directly from 5% or 8%more EDTA- or heparin-
blood, respectively. Adding the G59W mutation (Taq 3B plus
G59W) further improves tolerance, allowing Taq 1C2 to amplify
from 15% (EDTA-treated) or 28% (heparin-treated) more blood
compared to Taq E507K.
Heparin and hemoglobin/hemin (the most potent inhibitors
in blood) are thought to mimic and compete with duplex
DNA for binding to the polymerase active site (Byrnes et al.,
1975; Akane et al., 1994; Satsangi et al., 1994; Ghadessy et al.,
2001). Taq mutants with increased tolerance toward heparin
or blood have been described previously. After mutagenizing
four amino acids implicated in cold-sensitivity and overall per-
formance, Kermiekchiev et al. identified several substitutions
at E708 that dramatically (>30-fold) improve resistance of
Taq E626K/I707L and KlenTaq (N-truncated Taq) E626K/I707L
to blood, hemoglobin/hemin, soil extract, and humic acid
(Kermekchiev et al., 2009). Although no kinetic data were pro-
vided, results of a competitive filter-binding assay suggested that
generic resistance to PCR inhibitors was related to increased affin-
ity for DNA rather than diminished binding to hemin or humic
acid (Kermekchiev et al., 2009). With the possible exception of
humic acid, Taq E507K mutant exhibits a similarly-broad spec-
trum of resistance compared to wild-type (Taq E507K vs. Taq
E626K/I707L/E708Q: >45- vs. ∼100-fold for EDTA-blood; 0 vs.
2-fold for SYBR Green; 10- vs. 32-fold for SYBR in the presence
of blood; 2- vs. 8-fold for humic acid) in addition to increased
affinity for primer-template. E708 mutants have been commer-
cialized by DNA Polymerase Technology, Inc. under the trade
names OmniTaq (Taq E626K/I707L/E708Q) and OmniKlenTaq
(KlenTaq E626K/I707L/E708K) (Zhang et al., 2010).
As discussed above, E507 resides in the primer-template bind-
ing site where mutations are expected to modulate DNA binding
affinity. It’s less clear how substitutions at or near E708 con-
tribute to cold-sensitivity or increased DNA affinity/inhibitor
resistance, as this region lies at the hinge-point of the fingers,
away from the fingertip (which contacts incoming nucleotide and
single-stranded template) and portions of the thumb and palm
domains that interact with primer-template (Kermekchiev et al.,
2009). Taq E507K and E708Q mutants are further distinguished
by relative resistance to heparinized blood. Taq E507K tolerates
up to 45% EDTA-blood compared to 2% heparin-blood, sug-
gesting the combination of heparin and blood-associated (e.g.,
hemoglobin/hemin) inhibitors saturates a common (mutually-
exclusive) DNA/heme/heparin binding site. Alternatively, E507K
confers blood resistance by lowering sensitivity to NaCl, and
mutations at other positions confer resistance to DNA mimics
by reducing binding affinity for heme/heparin. In contrast to Taq
E507K, E708 mutants (OmniTaq, OmniKlenTaq) exhibit similar
tolerances to blood treated with EDTA, heparin, and citrate, con-
sistent with a unique mechanism of inhibitor resistance (Zhang
et al., 2010).
The heparin-binding site of Taq was precisely delineated by
Ghadessy et al. (2001), who used CSR selection with heparin to
identify a Taq mutant (Taq H15) with 130-fold higher resistance
to heparin and comparable (to wild-type Taq) affinity for DNA
in BIACore and template-dilution assays. Heparin resistance-
conferring mutations cluster in the DNA-binding domain, and
four of six residues mutated in Taq H15 make direct contacts
with either the primer (K540, N583) or template (D578, M747)
strand in open and closed forms of the binary/ternary complex
(Ghadessy et al., 2001).
By selecting for increased speed rather than blood/heparin
resistance, we and Kermekchiev et al. (2009) identified muta-
tions that confer increased DNA binding affinity and tolerance
for blood; curiously, the E507K mutant retained sensitivity to
heparin, while E708 mutants appear equally tolerant to EDTA-
blood and heparinized blood. In contrast, Ghadessy et al. (2001)
identified 6 mutations in H15 that collectively diminish heparin
binding without altering Kd (DNA), even though heparin is a
DNA mimic and the DNA-heparin binding sites are thought to
overlap. These findings can be reconciled if one assumes that
Taq makes additional contacts with primer-template outside the
DNA/heparin binding site. In the Ghadessy study, one or more of
the H15 mutations (K540, D578, N583, M747) may lower affin-
ity for DNA and heparin through the same mechanism, while the
remaining mutations restore Kd (equal to wild-type Taq) through
additional interactions with primer-template. Residing close to
K540, N583 and the 3′ primer terminus, E507 is close to the DNA-
heparin binding site, and introducing a positively-charged side
chain (E→K) may increase binding affinity for both DNA and
heparin (lower heparin tolerance). In contrast to E507, E708 lies
farther from primer-template binding site, where mutations that
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increase DNA binding affinity won’t necessarily enhance heparin
binding or sensitivity.
Among the other blood-resistant mutations identified here,
F749I is of particular interest due to its location relative to the
template strand. Although pointing inward, F749 is flanked by
amino acids that interact directly with heparin (M747) or the
template nucleoside opposing the incoming nucleoside triphos-
phate (R746, M747, N750). F749 is also thought to stack against
I707(Kermekchiev et al., 2003), which may provide a causal link
to the cold-sensitive (KlenTaq 706–708 mutants) and inhibitor-
resistant (Taq/KlenTaq 708 mutants) phenotypes identified by
Kermekchiev et al. (2003, 2009).
The contribution of mutations located outside the DNA-
binding pocket is more difficult to rationalize. In this study,
individual mutations G59W and V155I confer increased (by>15-
fold) resistance to EDTA-blood, while G59W improves ampli-
fication from heparinized blood (by 3.5-fold) when added to
Taq V155I/L245M/E507K/F749I. G59 and V155 reside in the
5′ structure-specific nuclease domain responsible for excising
Okazaki RNA during lagging strand synthesis (Li et al., 1998). The
5′ nuclease domain was implicated in an earlier study showing
that N-truncated Taq (KlenTaq; residues 279–882) can amplify
from 10- to 100-fold more blood (up to 5–10%) compared to
full-length Taq (Kermekchiev et al., 2009). KlenTaq also exhibits
higher thermostability and lower processivity compared to wild-
type, suggesting that point mutations in the 5′ nuclease domain
can modulate several properties of Taq that contribute to PCR
performance (Barnes, 1992). Mutations that increase PCR fit-
ness may alleviate the effects of other blood-associated inhibitors
(immunoglobulin G, lactoferrin, proteases) that inhibit PCR by
unknown means (Al-Soud and Radstrom, 1998, 2001; Al-Soud
et al., 2000).
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